{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:34:28Z","timestamp":1791516868138,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006954","name":"Tufts Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.healun.2019.12.008","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T11:43:43Z","timestamp":1579607023000},"page":"464-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-7362","authenticated-orcid":false,"given":"Ioana R.","family":"Preston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Bartolome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenat","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Krowka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert J.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wejdan F.","family":"Battarjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali M.","family":"Chakinala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardi","family":"Gomberg-Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2019.12.008_bib0001","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000001229","article-title":"International liver transplant society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension","volume":"100","author":"Krowka","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2019.12.008_bib0002","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4065\/71.6.543","article-title":"Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients","volume":"71","author":"Castro","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.healun.2019.12.008_bib0003","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90225-A","article-title":"Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics","volume":"100","author":"Hadengue","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.healun.2019.12.008_bib0004","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary hypertension: a report from the US-based REVEAL Registry","volume":"141","author":"Krowka","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.healun.2019.12.008_bib0005","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep.21431","article-title":"Portopulmonary hypertension: results from a 10-year screening algorithm","volume":"44","author":"Krowka","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.healun.2019.12.008_bib0006","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1164\/rccm.200804-613OC","article-title":"Portopulmonary hypertension: survival and prognostic factors","volume":"178","author":"Le Pavec","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2019.12.008_bib0007","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1055\/s-0037-1606251","article-title":"Portopulmonary hypertension","volume":"38","author":"Savale","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.healun.2019.12.008_bib0008","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0735-1097(87)80123-7","article-title":"Coexistent pulmonary and portal hypertension: morphologic and clinical features","volume":"10","author":"Edwards","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2019.12.008_bib0009","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0003319710369101","article-title":"Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation","volume":"61","author":"Pellicelli","year":"2010","journal-title":"Angiology"},{"key":"10.1016\/j.healun.2019.12.008_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1499-3872(11)60066-0","article-title":"Portopulmonary hypertension and serum endothelin levels in hospitalized patients with cirrhosis","volume":"10","author":"Tsiakalos","year":"2011","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.healun.2019.12.008_bib0011","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0761-8425(06)72078-2","article-title":"Porto-pulmonary hypertension[in French]","volume":"23","author":"Chabot","year":"2006","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.healun.2019.12.008_bib0012","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/lt.23407","article-title":"Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension","volume":"18","author":"Hollatz","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.healun.2019.12.008_bib0013","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.510300307","article-title":"Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension","volume":"30","author":"Krowka","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.healun.2019.12.008_bib0014","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1600-6143.2006.01432.x","article-title":"Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series","volume":"6","author":"Sussman","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2019.12.008_bib0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1378\/chest.10-0574","article-title":"Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension","volume":"139","author":"Cartin-Ceba","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.healun.2019.12.008_bib0016","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med 2002;346(16):1258]","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2019.12.008_bib0017","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.healun.2019.12.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights From the meta-analysis of 4894 patients From 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.healun.2019.12.008_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacc.2012.03.025","article-title":"Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension","volume":"60","author":"Ben-Yehuda","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2019.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1055\/s-0031-1273393","article-title":"Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension","volume":"49","author":"Halank","year":"2011","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.healun.2019.12.008_bib0021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/lt.21174","article-title":"Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol","volume":"13","author":"Fix","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.healun.2019.12.008_bib0022","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00007890-199702270-00020","article-title":"Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension","volume":"63","author":"Kuo","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2019.12.008_bib0023","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2019.12.008_bib0024","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2019.12.008_bib0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.healun.2016.12.014","article-title":"Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry","volume":"36","author":"Sithamparanathan","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2019.12.008_bib0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/lt.21479","article-title":"Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation","volume":"15","author":"Hemnes","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.healun.2019.12.008_bib0027","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/lt.21533","article-title":"Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension","volume":"15","author":"Gough","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.healun.2019.12.008_bib0028","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MAJ.0b013e31824184b1","article-title":"Epoprostenol-induced hypersplenism in portopulmonary hypertension","volume":"344","author":"Touma","year":"2012","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.healun.2019.12.008_bib0029","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccm.2013.08.008","article-title":"Portopulmonary hypertension","volume":"34","author":"Al-Naamani","year":"2013","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.healun.2019.12.008_bib0030","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1183\/09031936.05.00080804","article-title":"Bosentan therapy for portopulmonary hypertension","volume":"25","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2019.12.008_bib0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1183\/09031936.00117511","article-title":"Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension","volume":"41","author":"Savale","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2019.12.008_bib0032","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.healun.2019.12.008_bib0033","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1378\/chest.14-0193","article-title":"Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry","volume":"146","author":"Burger","year":"2014","journal-title":"Chest"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249820300115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249820300115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:39:02Z","timestamp":1760949542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249820300115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1053249820300115"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2019.12.008","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2019.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Heart and Lung Transplantation. All rights reserved.","name":"copyright","label":"Copyright"}]}}